Novartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader

Novartis is adding another weapon to its arsenal of oncology therapies, paying Arvinas $150 million upfront for rights to a phase 3-ready protein degrader that could treat a wide range of prostate cancer patients.